We are live on ! Find out more
Macquarie Group

Macquarie Group Portfolio holdings

AUM $16.8B
1-Year Est. Return 27.39%
This Fund
S&P 500
This Quarter Est. Return
+9.26%
1 Year Est. Return
+27.39%
3 Year Est. Return
+81.07%
5 Year Est. Return
+109.03%
10 Year Est. Return
+396.55%
AUM
$120B
AUM Growth
+$2.68B
Cap. Flow
-$4.47B
Cap. Flow %
-3.72%
Top 10 Hldgs %
12.85%
Holding
2,691
New
107
Increased
717
Reduced
1,008
Closed
96

Top Buys

Rank Stock Value
1
TJX icon
TJX Companies
TJX
+$505M
2
VRSN icon
VeriSign
VRSN
+$382M
3
BAX icon
Baxter International
BAX
+$374M
4
ADI icon
Analog Devices
ADI
+$219M
5
CHWY icon
Chewy
CHWY
+$206M

Sector Composition

Rank Sector Weight
1 Technology 25.17%
2 Healthcare 14.7%
3 Financials 13.17%
4 Industrials 10.74%
5 Consumer Discretionary 10.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MBWM icon
2451
Mercantile Bank Corp
MBWM
$1.01B
$10K ﹤0.01%
288
PTGX icon
2452
Protagonist Therapeutics
PTGX
$8.75B
$10K ﹤0.01%
307
SCL icon
2453
Stepan Co
SCL
$1.31B
$10K ﹤0.01%
84
SIGA icon
2454
SIGA Technologies
SIGA
$223M
$10K ﹤0.01%
1,355
TSHA icon
2455
Taysha Gene Therapies
TSHA
$1.59B
$10K ﹤0.01%
867
-1,343
-61% -$20.3K
LBAI
2456
DELISTED
Lakeland Bancorp Inc
LBAI
$10K ﹤0.01%
526
VIVO
2457
DELISTED
Meridian Bioscience Inc
VIVO
$10K ﹤0.01%
482
NTUS
2458
DELISTED
Natus Medical Inc
NTUS
$10K ﹤0.01%
425
BANC icon
2459
Banc of California
BANC
$3.28B
$9K ﹤0.01%
453
BRSP
2460
BrightSpire Capital
BRSP
$681M
$9K ﹤0.01%
877
RVMD icon
2461
Revolution Medicines
RVMD
$40.2B
$9K ﹤0.01%
352
SNN icon
2462
Smith & Nephew
SNN
$12.9B
$9K ﹤0.01%
248
+21
+9% +$721
URGN icon
2463
UroGen Pharma
URGN
$2B
$9K ﹤0.01%
959
GTHX
2464
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$9K ﹤0.01%
842
RAD
2465
DELISTED
Rite Aid Corporation
RAD
$9K ﹤0.01%
607
VVNT
2466
DELISTED
Vivint Smart Home, Inc. Class A Common Stock
VVNT
$9K ﹤0.01%
+919
New +$9.01K
ALBO
2467
DELISTED
Albireo Pharma Inc
ALBO
$9K ﹤0.01%
405
NPTN
2468
DELISTED
NEOPHOTONICS CORP
NPTN
$9K ﹤0.01%
615
-5,466
-90% -$71.9K
AKBA icon
2469
Akebia Therapeutics
AKBA
$327M
$8K ﹤0.01%
3,370
OSG
2470
Octave Specialty Group
OSG
$252M
$8K ﹤0.01%
514
AMRX icon
2471
Amneal Pharmaceuticals
AMRX
$5.72B
$8K ﹤0.01%
1,684
HSII
2472
DELISTED
Heidrick & Struggles
HSII
$8K ﹤0.01%
188
HSTM icon
2473
HealthStream
HSTM
$793M
$8K ﹤0.01%
292
NIC icon
2474
Nicolet Bankshares
NIC
$3.57B
$8K ﹤0.01%
90
NVO
2475
Novo Nordisk
NVO
$216B
$8K ﹤0.01%
148
-10
-6% -$542

Similar funds

Macquarie Group's Q4 2021 Portfolio in Review

As of Q4 2021, Macquarie Group held 2,691 positions worth $120B, up 2.3% from $117B the previous quarter. Its ten largest holdings account for 13% of the portfolio.

Macquarie Group withdrew a net $4.47B in Q4 2021, closing 96 positions and reducing 1,008 holdings. Its most notable exit was SK Telecom, an estimated $256M position sold in full.

By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 24% a quarter earlier, followed by Healthcare and Financials.

Against the trend, Macquarie Group opened a new position in GlobalFoundries worth $182M.

  • Macquarie Group's largest Q4 2021 buy was GlobalFoundries: 2,804,906 shares worth $182M.
  • Macquarie Group added most to TJX Companies in Q4 2021, an estimated $505M increase.
  • Macquarie Group's biggest Q4 2021 reduction was Meta Platforms (Facebook), cutting an estimated $733M.
  • Macquarie Group fully exited SK Telecom in Q4 2021, selling an estimated $256M.
  • Macquarie Group's ten largest holdings make up 13% of its $120B portfolio in Q4 2021.
  • Macquarie Group opened 107 new positions and closed 96 in Q4 2021.
  • Macquarie Group's portfolio value rose 2.3% quarter-over-quarter to $120B.

Based on Macquarie Group's 13F filing for Q4 2021, filed 11 Feb 2022.